Navigating Heart Health Risks During the Menopausal Transition

Roughly 6,000 women enter menopause each day in the United States, according to the National Institutes of Health, and the cardiometabolic changes of this window are where the cardiac risk math begins to shift.

The risk window opens years before the final period

Cardiovascular disease remains the leading cause of death in women, yet only 4 in 10 women identify it as their top health threat, per the joint guidance. By the time women reach menopause, roughly 90% carry at least one cardiovascular risk factor, and the transition itself accelerates several of them.

"Menopause represents an important opportunity for cardiovascular disease prevention," said Chrisandra L. Shufelt, M.D., M.S., FACP, MSCP, current board member and past president of The Menopause Society. "By the time women reach menopause, approximately 90% have at least one risk factor for heart disease, and we know that significant cardiometabolic changes occur during the menopause transition."

Menopause is not a cause of cardiovascular disease. The cardiometabolic shifts that cluster around it are measurable: LDL cholesterol trends upward, arterial walls stiffen, and blood pressure and glucose regulation drift. Many women enter this stage with no prior cardiac history, which is why the transition functions as a turning point rather than a quiet continuation.

Perimenopause is where the clinical work starts

The single date of menopause is a marker; the transition that drives cardiac risk spans years. Perimenopause, the window that can begin years before the final menstrual period, is when vasomotor symptoms, sleep disruption, weight changes, and palpitations most often surface, and when lipid and vascular changes accelerate.

Research from the Weizmann Institute of Science, analyzing more than 300 million test results from over 1 million women, identified abrupt physiological shifts around the final menstrual period across 52 of 90 categories of laboratory tests. The same dataset showed those changes were less pronounced in women receiving menopausal hormone therapy, a finding the authors interpret as evidence that the transition is a discrete biological event rather than a slow drift.

Numbers to track, and the clinical bottom line

The joint guidance narrows the clinical priority to three measurements: blood pressure, LDL cholesterol, and fasting glucose. For a patient in her 40s or early 50s, those values define the baseline against which post-menopausal shifts become visible. Kidney function rounds out the underdiscussed list: vascular and metabolic changes do not respect organ boundaries.

"Many women spend years preparing for pregnancy and motherhood, yet receive far less information about menopause before it begins," said Jen Ashton, M.D., M.S., an American Heart Association volunteer and board member, double board-certified in OB-GYN and obesity medicine. The clinical takeaway is direct: the same life stage that ends routine obstetric surveillance is the one that demands more aggressive cardiovascular monitoring.

The menopause transition is a quantifiable cardiovascular inflection point. It does not invent heart disease; it amplifies risk factors already present in roughly 9 out of 10 women. The clinical response is measurement: blood pressure, lipid panel, glucose, and renal function, obtained before the transition and repeated as symptoms emerge.